目的 探讨伏立康唑谷浓度的分布特征及其变异的影响因素,为个体化用药提供依据。方法 回顾性纳入某院接受伏立康唑治疗并行血药浓度监测的患者,收集患者临床资料,采用高效液相色谱法测定伏立康唑血药浓度。分析不同临床特征及合并用药下的谷浓度差异,计算患者日剂量标准化谷浓度,即谷浓度值除以其对应的日给药剂量,通过单因素与多因素线性回归分析查明影响伏立康唑暴露水平的独立因素。结果 本研究共纳入267例患者,伏立康唑日剂量范围为50~640 mg,11.6%的患者谷浓度低于有效浓度下限(<1.0 μg/mL),13.48%的患者谷浓度高于安全浓度上限(>5.5 μg/mL)。伏立康唑谷浓度与年龄和负荷剂量等因素显著相关。多因素回归分析显示,总胆红素是伏立康唑标准化谷浓度的独立影响因素(P<0.001)。结论 伏立康唑谷浓度个体差异显著,总胆红素水平可作为血药浓度变化的重要预测指标,对治疗药物监测指导下的个体化剂量调整具有临床参考价值。
Abstract
Objective To investigate the distribution characteristics of voriconazole trough concentrations and the factors influencing their variability, and to provide a basis for individualized therapy. Methods A retrospective study was conducted in patients receiving voriconazole therapy with therapeutic drug monitoring. Clinical data were collected and voriconazole plasma concentrations were determined using high-performance liquid chromatography. Differences in trough concentrations across clinical characteristics and concomitant medications were analyzed. The dose-normalized trough concentration (Cmin/Dose) was calculated as the trough concentration divided by the corresponding daily dose. Univariate and multivariate linear regression analyses were performed to identify independent factors affecting drug exposure. Results A total of 267 patients were included. The daily dose of voriconazole ranged from 50 to 640 mg. Among them, 11.6% of patients had trough concentrations below the effective lower limit (<1.0 μg/mL), and 13.48% exceeded the safety upper limit (>5.5 μg/mL). Trough concentrations were significantly associated with age and loading dose. Multivariate analysis identified total bilirubin as an independent factor influencing dose-normalized trough concentrations (P<0.001). Conclusion Voriconazole trough concentrations exhibit substantial interindividual variability. Total bilirubin may serve as an important predictor of concentration changes and has clinical value for individualized dosing under therapeutic drug monitoring.
关键词
伏立康唑 /
血药浓度 /
药物监测 /
日剂量标准化 /
个体化治疗
Key words
voriconazole /
plasma concentration /
drug monitoring /
dose-normalization /
individualized therapy
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WANG J, SUN J, YANG DW, et al.Appraisal of guidelines and variations in recommendations on drug therapy for invasive aspergillosis prevention and treatment[J]. Front Pharmacol, 2025, 16: 1443487.
[2] HUBRECHTS J, GIJSEN M, FLORE K, et al.Unravelling voriconazole's hepatic metabolism: a narrative review on factors impacting voriconazole-N-oxide exposure[J]. Mycoses, 2026, 69(2): e70158.
[3] SALEH A, SCHULZ J, SCHLENDER JF, et al.Understanding voriconazole metabolism: a middle-out physiologically-based pharmacokinetic modelling framework integrating in vitro and clinical insights[J]. Clin Pharmacokinet, 2024, 63(11): 1609-1630.
[4] TAKESUE Y, HANAI Y, ODA K, et al.Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring[J]. Clin Ther, 2022, 44(12): 1604-1623.
[5] 陈丽娟, 朱蕻潮, 吴晓丽, 等. 伏立康唑血药浓度监测在患者肝毒性和视觉症状不良反应预测诊断中的应用价值[J]. 中国新药与临床杂志, 2025, 44(2): 139-144.
[6] ASAI Y, KATO H, TAWARA I, et al.Potential of albumin-bilirubin score for estimating the voriconazole-induced hepatotoxicity undergoing therapeutic drug monitoring: a single-center retrospective cohort study[J]. Clin Ther, 2025, 47(4): 330-334.
[7] ZHAO YC, ZOU Y, HOU JJ, et al.Factors affecting voriconazole trough concentration and optimal maintenance voriconazole dose in Chinese children[J]. Antibiotics (Basel), 2021, 10(12): 1542.
[8] ZUBIAUR P, KNELLER LA, OCHOA D, et al.Evaluation of voriconazole CYP2C19 phenotype-guided dose adjustments by physiologically based pharmacokinetic modeling[J]. Clin Pharmacokinet, 2021, 60(2): 261-270.
[9] 赖芳圆, 朱理想, 刘婷, 等. 血液肿瘤科儿童伏立康唑谷浓度影响因素分析[J]. 今日药学, 2024, 34(12): 927-932.
[10] 彭敏, 黄攀豪, 邓银华, 等. 造血干细胞移植患者伏立康唑稳态谷浓度监测及其影响因素分析[J]. 中国临床药理学与治疗学, 2021, 26(6): 640-646.
[11] 郭冬杰, 李朋梅, 陈文倩, 等. 伏立康唑对肺移植患者术后他克莫司血药浓度影响的真实世界研究[J]. 中国药房, 2025, 34(20): 2519-2524.
[12] HINZE CA, FUGE J, GROTE-KOSKA D, et al. Factors influencing voriconazole plasma level in intensive care patients[J]. JAC Antimicrob Resist, 2024, 6(2): dlae045.
[13] 孙秀漫, 曾彩芳, 邓忠斌, 等. 肾移植患者伏立康唑血药谷浓度和不良反应的影响因素分析[J]. 中国药房, 2025, 36(18): 2301-2306.
[14] LING J, YANG X, DONG L, et al.Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis[J]. Front Pharmacol, 2024, 15: 1455721.
[15] MIAO Q, TANG JT, VAN GELDER T, et al.Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections[J]. Medicine (Baltimore), 2019, 98(3): e14137.
[16] ALLEGRA S, DE FRANCIA S, DE NICOLO A, et al.Effect of gender and age on voriconazole trough concentrations in Italian adult patients[J]. Eur J Drug Metab Pharmacokinet, 2020, 45(3): 405-412.
[17] DU YX, ZHU YX, LI L, et al.Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients[J]. Pharmacogenet Genomics, 2024, 34(6): 191-198.
[18] 中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会感染病学分会肝衰竭与人工肝学组. 肝衰竭诊治指南 (2024年版)[J]. 临床肝胆病杂志, 2024, 40(12): 2371-2387.
[19] RAKHSHAN A, RAHMATI KB, SAFFAEI A, et al.Hepatotoxicity induced by azole antifungal agents: a review study[J]. Iran J Pharm Res, 2023, 22(1): e130336.
[20] NASHIMOTO S, SUGAWARA M, TAKEKUMA Y.Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin-bilirubin (ALBI) score of patients with liver dysfunction[J]. J Infect Chemother, 2025, 31(8): 102766.
基金
湖南省自然科学基金项目“肠道菌介导伏立康唑肝毒性的机制研究”(2023JJ60104)